BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 25488786)

  • 1. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
    Poddubnyy D; Gensler LS
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
    Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
    Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we reduce the dosage of biologics in spondyloarthritis?
    Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
    Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
    Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
    Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional study on clinical characteristics of Saudi axial spondylarthritis: preliminary results.
    Bedaiwi MK; AlRasheed RF; Bin Zuair A; Alqurtas EM; Baeshen MO; Omair MA
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5241-5247. PubMed ID: 34486699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
    Cruz-Machado AR; Rodrigues-Manica S; Silva JL; Alho I; Coelho C; Duarte J; Florêncio C; Pimentel-Santos FM; Tavares-Costa J; Vieira-Sousa E
    Rheumatology (Oxford); 2020 Nov; 59(11):3158-3171. PubMed ID: 32696064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
    Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Axial spondyloarthritis and ankylosing spondylitis].
    Nordström D; Kauppi M
    Duodecim; 2010; 126(12):1467-74. PubMed ID: 20617750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.
    Paramarta JE; De Rycke L; Ambarus CA; Tak PP; Baeten D
    Rheumatology (Oxford); 2013 Oct; 52(10):1873-8. PubMed ID: 23861532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):108-13. PubMed ID: 23740231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
    Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New evidence on the management of spondyloarthritis.
    Sieper J; Poddubnyy D
    Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASAS classification criteria for axial spondyloarthritis: time to modify.
    Akkoc N; Khan MA
    Clin Rheumatol; 2016 Jun; 35(6):1415-23. PubMed ID: 27094940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept for treating axial spondyloarthritis.
    Guillot X; Prati C; Sondag M; Wendling D
    Expert Opin Biol Ther; 2017 Sep; 17(9):1173-1181. PubMed ID: 28682112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.
    Mitulescu TC; Popescu C; Naie A; Predeţeanu D; Popescu V; Alexandrescu C; Voinea LM
    J Med Life; 2015; 8(3):319-25. PubMed ID: 26351533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):101-7. PubMed ID: 23696633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Associations of Uveitis in Axial Spondyloarthritis Group and Ankylosing Spondylitis Group: Do They Represent the Same Disease?
    Wong OM; Tsang HHL; Chan SCW; Lee KH; Li PH; Lau CS; Chung HY
    J Clin Rheumatol; 2020 Jan; 26(1):1-6. PubMed ID: 30028807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.